Key Highlights

  • Third-quarter Revenue reached USD 5.1 million against USD 1.3 million a year earlier, lifted by two acquired radiopharmacies, a larger PET Labs Business and USD 0.9 million of LNG sales from Renergen.
  • Selling, general and administrative expense rose to USD 34.1 million from USD 12.1 million, pushing total operating expenses to USD 41.3 million and the net loss to USD 30.9 million.
  • A USD 11.25 million gain on extinguishing convertible notes partly offset the operating loss, after holders exchanged about USD 109.2 million of notes for 23,160,682 shares in July.
  • Cash and cash equivalents stood at USD 201.7 million on September 30, 2026, while nine-month operating cash outflow was USD 66.4 million and shares outstanding were 155,834,430.

Acquired Radiopharmacies and LNG Lift Revenue Fourfold

ASP Isotopes (NASDAQ:ASPI) filed its Quarterly Report on November 16, 2026 for the three months ended September 30, 2026. Revenue was USD 5.124 million versus USD 1.271 million, about four times higher (calculated). Radiopharmacy dose sales made up USD 4.3 million, helped by the Numed and East Coast Nuclear Pharmacy acquisitions and stronger PET Labs volumes, while LNG from the Renergen purchase added USD 0.9 million. The company develops isotope enrichment technology for nuclear medicine, semiconductors and nuclear energy, and says it has not yet sold any enriched isotopes. Gross Profit was USD 0.8 million, a Margin of about 15% (calculated) against 19% a year earlier.

SG&A Surge Outweighs the USD 11.25 Million Debt Gain

Operating costs grew far faster than sales. Research and Development reached USD 7.2 million from USD 3.1 million, and selling, general and administrative expense climbed to USD 34.1 million from USD 12.1 million. Total operating expenses were USD 41.3 million against USD 15.2 million. Other income of USD 10.8 million included a USD 11.25 million gain on extinguishing convertible notes and USD 4.3 million of interest income, offset by USD 3.5 million of interest expense. The loss before income tax was USD 29.7 million, and the net loss was USD 30.9 million. The loss attributable to shareholders was USD 30.4 million, or USD 0.21 a share, versus USD 0.14.

Helium Losses, Phase 2 Funding and the ENDRA Merger

Cash and equivalents were USD 201.7 million, and management expects them to fund operations for at least the next 12 months. Nine-month operating cash outflow was USD 66.4 million, and the nine-month net loss was USD 72.0 million after USD 19.6 million of income from discontinued operations. The Helium and LNG segment posted a negative gross margin of 96% because fixed plant costs exceeded production volumes, and management expects improvement in 2027. Phase 2 of the Virginia Gas Project is estimated to cost above USD 1.0 billion, with no binding debt agreements signed. The company also plans a Merger involving ENDRA and a separation of its nuclear fuels unit, and targets initial Si-28 shipments in the fourth quarter of 2026.

Where Things Stand

The loss widened because spending on administration and research outpaced a fourfold rise in acquired revenue. ASP Isotopes (NASDAQ:ASPI) lost USD 30.9 million on USD 5.1 million of sales, with SG&A of USD 34.1 million the largest driver, even after a USD 11.25 million gain on retired convertible notes. The Balance Sheet is the cushion, with USD 201.7 million of cash. Next markers are the first enriched Si-28 shipments targeted for the fourth quarter, Helium and LNG margin progress, Phase 2 financing talks and the ENDRA merger vote.